Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes

Trial Profile

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Pegvisomant (Primary)
  • Indications Insulin resistance
  • Focus Therapeutic Use
  • Acronyms PEGIR
  • Most Recent Events

    • 12 May 2016 Status changed from active, no longer recruiting to completed.
    • 16 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top